Cancer media resource company CURE Media Group stated on Monday that Lung Cancer Alliance is now part of the former's Strategic Alliance Partnership (SAP) Programme to empower the lung cancer community through educational efforts.
The SAP Programme is designed to facilitate an open exchange of information among trusted peers, with focus in improving care in the lung cancer community.
Under the terms of the partnership, Lung Cancer Alliance will share valuable content through CURE magazine, readers will have access to unprecedented resources including the latest research, interviews and articles, as well as help patients with cancer and their caregivers make better informed decisions.
Established in 1995, Lung Cancer Alliance is a leading non-profit health organisations committed to serving the lung cancer community. It empowers a caring community by helping people navigate the paths of early detection, diagnosis, treatment and long-term survival. It leverages insights into the lung cancer community to improve care, amplify awareness, drive advocacy and lead transformative research, with the vision of tripling survivors in the next decade.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA